Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group-Reference-Cited by-同舟云学术

Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group

Published:2012-08 Issue:8 Volume:36 Page:990-997
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Nomdedéu J.,Hoyos M.,Carricondo M.,Esteve J.,Bussaglia E.,Estivill C.,Ribera J.M.,Duarte R.,Salamero O.,Gallardo D.,Pedro C.,Aventin A.,Brunet S.,Sierra J.

Funder

Fundación Mutua Madrileña to JN

Plà de Recerca de Catalunya, Marató de TV3

Fundació Cellex, Spain

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference36 articles.

1. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia;Schlenk;N Engl J Med,2008

2. An integrated genomic analysis of human glioblastoma multiforme;Parsons;Science,2008

3. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas;Watanabe;Am J Pathol,2009

4. Recurring mutations found by sequencing an acute myeloid leukemia genome;Mardis;N Engl J Med,2009

5. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms;Green;N Engl J Med,2010

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis;Blood Advances;2023-10-02

2. Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia;Pathogenesis and Treatment of Leukemia;2023

3. Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis;Frontiers in Oncology;2022-11-28

4. Role of Biomarkers in the Management of Acute Myeloid Leukemia;International Journal of Molecular Sciences;2022-11-22

5. Prognostic relevance of combined IDH1 and NPM1 mutations in the intermediate cytogenetic de novo acute myeloid leukemia;Cellular and Molecular Biology;2021-11-25